Related Experiment Video

Updated: May 2, 2026

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

2.6K

Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity

Nelson Ung1, Tracy L Putoczki2, Stanley S Stylli3

  • 1Department of Surgery; The University of Melbourne; The Royal Melbourne Hospital; Parkville, VIC Australia.

Cancer Biology & Therapy
|February 22, 2014
PubMed

Insights

Signal transducer and activator of transcription 3 (STAT3) activity correlates with resistance to epidermal growth factor receptor (EGFR) inhibitors in cancer. Inhibiting STAT3 alongside EGFR therapy may improve treatment efficacy for metastatic colorectal cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Epidermal growth factor receptor (EGFR) inhibitors are FDA-approved for various cancers, including metastatic colorectal cancer (mCRC).
  • Many patients exhibit primary resistance or acquire resistance to anti-EGFR therapies, limiting their clinical effectiveness.

Purpose of the Study:

  • To investigate the correlation between Signal transducer and activator of transcription 3 (STAT3) activity and the efficacy of anti-EGFR inhibitors.
  • To explore the role of STAT3 in mediating resistance to anti-EGFR therapies in cancer models.

Main Methods:

  • Assessed the efficacy of anti-EGFR inhibitors in correlation with STAT3 activity in various cancer cell lines (A431, colon cancer lines).
  • Utilized tumor xenograft models to evaluate the impact of cetuximab on tumor growth and STAT3 activity.
  • Investigated the effect of protein tyrosine phosphatase receptor delta (PTPRD) knockdown on cetuximab resistance.
  • Examined the re-sensitization of resistant cancer cells to EGFR inhibitors upon STAT3 inhibition.

Main Results:

  • A clear correlation was observed between anti-EGFR inhibitor efficacy and STAT3 inhibition in cancer cell lines and xenografts.
  • STAT3 inhibition reversed cetuximab resistance induced by PTPRD knockdown.
  • Acquired resistance to EGFR inhibitors was associated with increased STAT3 activity.
  • Co-treatment with STAT3 inhibitors re-sensitized resistant cells to multiple EGFR inhibitors.

Conclusions:

  • STAT3 activity plays a crucial role in promoting resistance to anti-EGFR therapy.
  • Combining anti-EGFR therapy with STAT3 inhibitors may offer a therapeutic strategy for EGFR-driven tumors, including mCRC.
Keywords:
EGFRSTAT3cetuximabcolon cancer

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

8.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
15.3K